Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

Journal of Managed Care Pharmacy
doi 10.18553/jmcp.2009.15.7.543
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Academy of Managed Care Pharmacy

Related search

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics

Archives of Neurology
1999English

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Pnd60 - Cost-Effectiveness of Teriflunomide for the Treatment of Relapsing-Remitting Multiple Sclerosis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd73 - The Impact of Modelling Subsequent Treatment on Estimates of Cost-Effectiveness: An Analysis of Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd120 - Treatment Decisions About First-Line Disease-Modifying Treatments (Dmts) in Relapsing Remitting Multiple Sclerosis: A Systematic Review of Patient Needs and Preferences

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comparing the Quality of Life Among Patients With Relapsing Remitting Multiple Sclerosis in Iraq Using Different Disease Modifying Therapies

Iraqi Journal of Pharmaceutical Sciences
ToxicologyAnalytical ChemistryPharmaceuticsPharmacology
2018English

Characteristics of Pediatric Patients With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Agents

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England

Journal of Medical Economics
Health Policy
2018English

Pnd65 - Cost-Effectiveness Analysis of Drugs Used for the Treatment of Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy